Liminatus Pharma (NASDAQ:LIMN) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Liminatus Pharma (NASDAQ:LIMN – Free Report) to a strong sell rating in a report published on Saturday morning.

Separately, Weiss Ratings upgraded shares of Liminatus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Get Liminatus Pharma alerts:

Get Our Latest Stock Report on LIMN

Liminatus Pharma Stock Down 8.3%

Shares of LIMN stock opened at $5.16 on Friday. The company’s fifty day simple moving average is $5.84 and its 200-day simple moving average is $11.80. The firm has a market cap of $5.21 million, a PE ratio of -0.22 and a beta of 5.35. Liminatus Pharma has a 12 month low of $4.75 and a 12 month high of $203.00.

Liminatus Pharma (NASDAQ:LIMN – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($1.50) EPS for the quarter.

Liminatus Pharma Company Profile

(Get Free Report)

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Read More

• Five stocks we like better than Liminatus Pharma
• 2 Biotech Stocks Shaping Up for Major Breakouts
• 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
• 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
• Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?

Receive News & Ratings for Liminatus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminatus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.